|
Imiquimod tested as cervical dysplasia therapy. (Immune-Response Modifiers).
Publication: Internal Medicine News Publication Date: 15-FEB-02 Author: Zoler, Mitchel L.
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2002 International Medical News Group
A topical drug that boosts the immune system and is delivered intravaginally may have a role in treating low-grade cervical dysplasia.
The prototype agent of this kind, imiquimod (Aldara), has been tested in a recently completed phase II study that included 130 women with low-grade squamous intraepithelial lesions. The study was sponsored by the drug's manufacturer, 3M.
A completed analysis of the results is not expected until next year. "We're aware of the anecdotal experience (of physicians using imiquimod in practice),...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Internal Medicine News |
Nicostatin, rosuvastatin, ezetimibe to debut soon. (Excellent Safety P...
February 15, 2002
|
Aldosterone antagonism: New insights and clinical implications for hea...
February 15, 2002
|
PEG-Intron, Rebetol Study looks at doses in HCV. (Postmarketing Study ...
February 15, 2002
|
Few relapse if HCV response is sustained 6 mos after therapy. (Pegylat...
February 15, 2002
|
Pegylated interferon alfa-2b, ribavirin best against fibrosis. (Out of...
February 15, 2002
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
